Table 3.
Clinical and echocardiographic differences between participants with new discovered atrial fibrillation and those without (n=93)
| AF (28) | Non-AF (65) | P value | |
| Female, n (%) | 15 (55.6) | 34 (52) | ns |
| NT-proBNP level, median (Q1–Q3) | 1284.5 (1015–2000) | 1178 (989.5–1531) | ns |
| Hypertension, n (%) | 21 (75) | 48 (37.9) | ns |
| Diabetes mellitus, n (%) | 6 (21.4) | 15 (23.1) | ns |
| Vascular disease, n (%) | 4 (4.3) | 15 (16.1) | ns |
| Glomerular filtration rate, median (Q1–Q3) | 65 (50–77) | 62 (44–73) | ns |
| Body mass index, median (Q1–Q3) | 24.7 (23.6–27.9) | 25.2 (22.4–27.5) | ns |
| Left atrial volume index, mL/m2 (2*), median (Q1–Q3) | 44 (35.00–50.20) | 34 (29.00–41.50) | 0.002 |
| Left ventricular mass (13*), median (Q1–Q3) | 96 (72.00–123.00) | 96 (83.00–137.00) | ns |
| E/é ratio (21*), median (Q1–Q3) | 13 (9.2–14.30) | 11 (9.00–14.00) | ns |
| Pulmonary artery pressure mm Hg, median (Q1–Q3) | 38 (30.00–41.00) | 32 (26.00–36.00) | 0.025 |
*Missing data (inadequate echocardiographic view).
é, average peak early diastolic tissue velocity; AF, atrial fibrillation; E, mitral peak velocity; NT-proBNP, N-terminal pro-B-type natriuretic peptide; Q1, first quartile; Q3, third quartile.